Loading article...
Loading article...
Stream/Area:
-
Subject:
-
Paper ID:
IJSREM65521
Volume:
10 |
6 |
Jun 2026
Pages:
1-7
Publication Frequency:
Monthly (12 issues per year)
License:International Journal of Scientific Research in Engineering and Management follows the Creative Commons Attribution 4.0 (CC BY 4.0) License, allowing free use and distribution with proper attribution.
Department of Pharmacy
Kharvel Subharti College Of Pharmacy
Department of Pharmacy
Delhi Pharmaceutical Sciences and Research University, New Delhi
The goal of the current investigation was to determine if Areca catechu might protect Wister albino rats from developing Parkinson's disease (PD) triggered by Rotenone. Globally, the frequency and incidence of PD are concerning developments. In affluent nations, the extension of human life is increasingly accompanied with a rise in neurodegenerative illnesses, the majority of which have merely symptomatic treatments rather than effective therapies. Plant based therapy have piqued the scientific community's attention in recent years. Neuroinflammation, oxidative stress, and apoptosis are presently proposed factors underlying the etiology of Parkinson's disease (PD). Current understanding of the PD pathophysiology has changed with the identification of several gene variants over the last 10 years, which could offer insight into the processes behind the pathogenesis of atypical instances of PD. Many antiparkinsonian medications have been created for the conduct of Parkinson's disease, but unfortunately, their possible adverse effects have caused physicians to seriously worry about their usage. In this direction, we therefore, planned to explore the antiparkinsonian effect of Areca catechu against Rotenone-induced PD in Wister albino rats. Animals were separated into 6 groups: Normal control; Toxic (Rotenone 1.5 mg/kg); Areca catechu + Rotenone [I]; Areca catechu + Rotenone [II]; Areca catechu per se; Levodopa-carbidopa + Rotenone. Dosing was done for 28 days along with a daily dose of Rotenone for 28 days and after last day of dosing, weight of all animals were weighed individually before sacrificing of the animals. On the 29th day, animals were sacrificed and various biochemical parameters pertaining to TBARS, GSH, Catalase, and SOD were estimated in the blood after serum separation by homogenizer at 3000 RPM for 15 min. Apart from biochemical parameters, various neurobehavioral tests including Beam crossing task (BCT), Morris water maze (MWM), Rotarod Test, Forced swim test (FST), and Catalepsy test were also performed to establish the antiparkinsonian effect of Areca catechu. In the end, in our study found that Areca catechu showed a potent antiparkinsonian effect against Rotenone-induced Parkinson's disease.
KEYWORDS
In conclusion, our work suggests that supplementing with Areca catechu can shield rats' serum and brain tissues against oxidative damage brought on by Rotenone. Areca catechu have potent antioxidant effects through up and down-regulating brain function. In cases of Rotenone-induced Parkinson disease, Areca catechu may also support memory and learning function, antioxidant activity, and potential therapeutic effectiveness. Although the precise link is found between oxidative stress and Parkinson disease, several studies have recommended that oxidative tension might be a major factor in several illnesses, particularly those that affect the neurological system. A conventional pharmacological therapy group might also be added to this model as a constraint for this investigation. As a result, our research has demonstrated that Areca catechu can lessen Rotenone-induced learning and memory impairment as well as oxidative damage by taking part in a diversity of biological progressions like antioxidant, anti-apoptotic, and anti-inflammatory impacts on nitric oxide pathways.
Arvidsson, M. B., Löwhagen, O., & Rak, S. (2007). Early and late phase asthmatic response in lower airways of cat-allergic asthmatic patients – a comparison between experimental and environmental allergen challenge. Allergy, 62(5), 488-494. doi:10.1111/j.1398-9995.2007.01278.x Bashkatova, V., Alam, M., Vanin, A., & Schmidt, W. J. (2004). Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Experimental Neurology, 186(2), 235-241. Benninger, D., Waldvogel, D., & Bassetti, C. L. (2008). REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology, 71(12), 955-956. Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303. Dorsey, E., Elbaz, A., Nichols, E., Abd-Allah, F., Abdelalim, A., Adsuar, J., . . . Collado-Mateo, D. (2018). GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 17(11), 939-953. Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., . . . Lees, A. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351(24), 2509-2518. Gaweda-Walerych, K., Maruszak, A., Safranow, K., Bialecka, M., Klodowska-Duda, G., Czyzewski, K., . . . Opala, G. (2008). Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson’s disease risk in a Polish PD cohort. Journal of neural transmission, 115, 1521-1526. Hawkes, C. (1995). Diagnosis and treatment of Parkinson's disease. Anosmia is a common finding. BMJ: British Medical Journal, 310(6995), 1668. Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992). What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology, 42(6), 1142-1142. Hughes, A. J., Daniel, S. E., Ben‐Shlomo, Y., & Lees, A. J. (2002). The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 125(4), 861-870. Ishola, I. O., Balogun, A. O., & Adeyemi, O. O. (2020). Novel potential of metformin on valproic acid‐induced autism spectrum disorder in rats: involvement of antioxidant defence system. Fundamental & clinical pharmacology, 34(6), 650-661. Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., . . . Wenning, G. K. (2003). Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Movement disorders: official journal of the Movement Disorder Society, 18(5), 467-486.
Publication Date
6/26/2026
Peer Review Type
Double-Blind Peer Review
Review Rounds: 2
Documents
Article Views
0
Total views since publication
PDF Downloads
6
Total downloads since publication
Geographic Reach
5
Digital Preservation: This article is permanently archived on Zenodo and complies with all data preservation standards across major indexing platforms.
Plagiarism Screening
This manuscript has been checked for plagiarism using TurnitinPlagiarismChecker software.
Conflict of Interest
The authors declare no conflict of interest related to this research work.
Funding Information
No funding information available for this research.
Related research in the same subject area
Loading similar articles...